(Q40162812)

18 September 2017

A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin? (English)

1 reference

18 September 2017

0 references

2

1 reference

18 September 2017

3

1 reference

18 September 2017

7

1 reference

18 September 2017

Michael Groessl

4

0 references

Michael A. Jakupec

object named as

Michael A Jakupec

series ordinal

6

0 references

Seied M Valiahdi

series ordinal

5

object named as

Seied-M Valiahdi

1 reference

18 September 2017

Isabella Berger

1

1 reference

18 September 2017

1 April 2007

1 reference

18 September 2017

1 reference

18 September 2017

2

1 reference

18 September 2017

505-514

1 reference

18 September 2017

4

1 reference

Platinum complexes as anticancer agents

18 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

Platinum Compounds: a New Class of Potent Antitumour Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Essential drugs for cancer therapy: a World Health Organization consultation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Tumour-inhibiting platinum complexes--state of the art and future perspectives.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

On the Origin of Cancer Cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Why do cancers have high aerobic glycolysis?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Platinum(II) and technetium(I) complexes anchored to ethynylestradiol: a way to drug targeting and delivery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Capillary electrophoresis in anti-cancer metallodrug research: advances and future challenges

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Metallodrug research and analysis using capillary electrophoresis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Slowly Exchangingcis-PtA2B2 Atropisomers with A2 = Chiral Diamine Ligands and B = 5,6-Dimethylbenzimidazole

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5'-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600279

7 January 2021

Identifiers

DOI

10.1002/CMDC.200600279

1 reference

18 September 2017

1 reference

PubMed ID

17340670